A lot of people argue that our lives are basically about finding answers to all the questions we encounter over the course of it. Each question is masterfully planned to make us push our limits, both mentally and physically, and become better. This theory has stood the test of time, but it managed that mainly because the theory matches our aspirations as human beings. We might have hugely different goals and dreams, however on an intrinsic level, all of us aspire to find certain answers. The questions are rarely similar, but our willingness to find responses for them holds a close resemblance. This collective aspiration is what breeds the idea of a greater good, and this is what drives creations like technology into the daylight.
In its early days, technology didn’t have many fans. Instead, many people were quick to deem it a hoax on the basis that most of what it promised wasn’t feasible to achieve. Nevertheless, a small group of people continued to believe in the utopian future of tech-driven tools and a simplified world, and credit to them as we have all of that today. Even though the impact of technology’s growth has been continuously felt across a wider spectrum, much of its more contributions have come in the medical field. The unveiling of the MedTech sector has benefited an immeasurable number of people. Not only it has saved so many lives, but it has also changed people’s flawed perception of healthcare. For years, majority of individuals have had reservations about consulting a doctor for variety of issues. However, enhanced quality of consultation and treatments have brought the patients and medical professionals closer, encouraging better understanding, and consequentially, better health. Nevertheless, certain health-related areas still remain slightly less developed. For instance, now we do have cancer treatments available at our disposal, but the efficiency of them has long been questionable.
To make a stride in this aspect, pharmtech companies, Terumo Blood, Cell Technologies, and PhotonPharma have officially joined forces. The announcement of the collaboration came up on 11th August 2021 through a press release, which revealed an MOU has been signed to develop innocell. Innocell is a novel tumor-specific immunotherapy that will work against solid tumors.
The MOU agreement details go on to shed light on each company’s role in this collaboration. PhotonPharma will act as the primary manufacturer in this deal. It will use Terumo’s mirasol pathogen reduction technology to develop cancer immunotherapy. Terumo Blood along with Cell Technologies is also going to provide mirasol illuminators and single use sets for the preparation of an immunotherapy plan that will be executed during clinical trials.
All the involved companies have indicated that a long-term collaboration is on the cards.
